Prostate Cancer Reports


Volume 2 Supplement 12
  December 2014

Home > Prostate Cancer Reports > Volume 2 - Year 2014 > Supplement 12, December 2014

CONTENTS



Case reports
Detection, diagnosis and evaluation
Epidemiology and risk factors
Etiology and pathogenesis
Integrative medicine
Overall management
Prognosis and outcome
Quality of life
Staging
Treatment


CASE REPORTS



Brunocilla E, Schiavina R, Nanni C, Borghesi M, Cevenini M, Molinaroli E, Vagnoni V, Castellucci P, Ceci F, Fanti S, Gaudiano C, Golfieri R, Martorana G.
First case of 18F-FACBC PET/CT-guided salvage radiotherapy for local relapse after radical prostatectomy with negative 11C-Choline PET/CT and multiparametric MRI: New imaging techniques may improve patient selection.
Arch Ital Urol Androl. 2014 Sep 30;86(3):239-40. doi: 10.4081/aiua.2014.3.239.
Abstract | Full text | Related citations


Haut MJ, Harryhill JF, Rosenstock J, Warhol MJ, Vitti R.
Progressing prostate carcinoma.
Oncologist. 2001;6(2):183-96.
Abstract | Full text | Related citations

DETECTION, DIAGNOSIS AND EVALUATION



Garcia JR, Cuberas G, Riera E, Soler M, Moragas M, Lomeña F.
Dual-phase 11C-choline PET/computed tomography in the early evaluation of prostate cancer recurrence.
Nucl Med Commun. 2015 Jan;36(1):8-15. doi: 10.1097/MNM.0000000000000207.
Abstract | Related citations


Goldstein J, Even-Sapir E, Ben-Haim S, Saad A, Spieler B, Davidson T, Berger R, Weiss I, Appel S, Lawrence YR, Symon Z.
Does Choline PET/CT Change the Management of Prostate Cancer Patients With Biochemical Failure?
Am J Clin Oncol. 2014 Nov 4. [Epub ahead of print]
Abstract | Related citations


Murray NP, Reyes E, Orellana N, Fuentealba C, Dueñas R.
Elimination of primary circulating prostate cells after radical prostatectomy for prostate cancer decreases the risk of future biochemical failure.
Arch Esp Urol. 2014 Oct;67(8):684-91.
Abstract | Related citations


Picchio M, Castellucci P.
Clinical Indications of C-Choline PET/CT in Prostate Cancer Patients with Biochemical Relapse.
Theranostics. 2012;2(3):313-7. doi: 10.7150/thno.4007. Epub 2012 Mar 12.
Abstract | Full text | Related citations


Rodado-Marina S, Coronado-Poggio M, García-Vicente AM, García-Garzón JR, de la Jara AC, Maldonado-Suárez A, Rodríguez-Fernández A.
Clinical utility of 18 F-fluorocholine PET-CT in biochemical relapse of prostate cancer after radical treatment. Results of a multicentre study.
BJU Int. 2014 Oct 13. doi: 10.1111/bju.12953. [Epub ahead of print]
Abstract | Related citations

EPIDEMIOLOGY AND RISK FACTORS



Moreira DM, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Boffetta P, Freedland SJ.
Cigarette smoking is associated with an increased risk of biochemical disease recurrence, metastasis, castration-resistant prostate cancer, and mortality after radical prostatectomy: results from the SEARCH database.
Cancer. 2014 Jan 15;120(2):197-204. doi: 10.1002/cncr.28423. Epub 2013 Oct 11.
Abstract | Related citations


Taneja SS.
Re: cigarette smoking is associated with an increased risk of biochemical disease recurrence, metastasis, castration-resistant prostate cancer, and mortality after radical prostatectomy: results from the SEARCH database.
J Urol. 2014 Jun;191(6):1784. doi: 10.1016/j.juro.2014.03.065. Epub 2014 Mar 20.
Abstract | Full text | Related citations

ETIOLOGY AND PATHOGENESIS



Chéry L, Lam HM, Coleman I, Lakely B, Coleman R, Larson S, Aguirre-Ghiso JA, Xia J, Gulati R, Nelson PS, Montgomery B, Lange P, Snyder LA, Vessella RL, Morrissey C.
Characterization of single disseminated prostate cancer cells reveals tumor cell heterogeneity and identifies dormancy associated pathways.
Oncotarget. 2014 Oct 30;5(20):9939-51.
Abstract | Full text | Related citations


Karantanos T, Evans CP, Tombal B, Thompson TC, Montironi R, Isaacs WB.
Understanding the Mechanisms of Androgen Deprivation Resistance in Prostate Cancer at the Molecular Level.
Eur Urol. 2014 Oct 8. pii: S0302-2838(14)01000-8. doi: 10.1016/j.eururo.2014.09.049. [Epub ahead of print]
Abstract | Full text | Related citations


Passoni NM, Polascik TJ.
Words of wisdom. Re: Tracking the clonal origin of lethal prostate cancer.
Eur Urol. 2014 Aug;66(2):390-1. doi: 10.1016/j.eururo.2014.05.022.
Abstract | Full text | Related citations


Pavese JM, Bergan RC.
Circulating tumor cells exhibit a biologically aggressive cancer phenotype accompanied by selective resistance to chemotherapy.
Cancer Lett. 2014 Oct 1;352(2):179-86. doi: 10.1016/j.canlet.2014.06.012. Epub 2014 Jul 10.
Abstract | Related citations


Small EJ.
Can targeting the androgen receptor in localized prostate cancer provide insights into why men with metastatic castration-resistant prostate cancer die?
J Clin Oncol. 2014 Nov 20;32(33):3689-91. doi: 10.1200/JCO.2014.57.8534. Epub 2014 Oct 13.
Abstract | Full text | Related citations

INTEGRATIVE MEDICINE



Allott EH, Howard LE, Cooperberg MR, Kane CJ, Aronson WJ, Terris MK, Amling CL, Freedland SJ.
Serum Lipid Profile and Risk of Prostate Cancer Recurrence: Results from the SEARCH Database.
Cancer Epidemiol Biomarkers Prev. 2014 Nov;23(11):2349-56. doi: 10.1158/1055-9965.EPI-14-0458. Epub 2014 Oct 10.
Abstract | Full text | Related citations


Dell'Atti L.
Correlation between prolonged use of aspirin and prognostic risk in prostate cancer.
Tumori. 2014 Sep-Oct;100(5):486-90. doi: 10.1700/1660.18156.
Abstract | Related citations


Gerstenberger JP, Bauer SR, Van Blarigan EL, Sosa E, Song X, Witte JS, Carroll PR, Chan JM.
Selenoprotein and antioxidant genes and the risk of high-grade prostate cancer and prostate cancer recurrence.
Prostate. 2015 Jan;75(1):60-9. doi: 10.1002/pros.22892. Epub 2014 Oct 4.
Abstract | Related citations


Jacobs EJ, Newton CC, Stevens VL, Campbell PT, Freedland SJ, Gapstur SM.
Daily aspirin use and prostate cancer-specific mortality in a large cohort of men with nonmetastatic prostate cancer.
J Clin Oncol. 2014 Nov 20;32(33):3716-22. doi: 10.1200/JCO.2013.54.8875. Epub 2014 Oct 20.
Abstract | Related citations


Naiki-Ito A, Chewonarin T, Tang M, Pitchakarn P, Kuno T, Ogawa K, Asamoto M, Shirai T, Takahashi S.
Ellagic acid, a component of pomegranate fruit juice, suppresses androgen-dependent prostate carcinogenesis via induction of apoptosis.
Prostate. 2014 Oct 4. doi: 10.1002/pros.22900. [Epub ahead of print]
Abstract | Related citations


Song C, Park S, Park J, Shim M, Kim A, Jeong IG, Hong JH, Kim CS, Ahn H.
Statin use after radical prostatectomy reduces biochemical recurrence in men with prostate cancer.
Prostate. 2014 Oct 18. doi: 10.1002/pros.22907. [Epub ahead of print]
Abstract | Related citations

OVERALL MANAGEMENT



Cassinello J, Climent MA, González Del Alba A, Mellado B, Virizuela JA.
SEOM Clinical guidelines for the treatment of metastatic prostate cancer.
Clin Transl Oncol. 2014 Dec;16(12):1060-6. doi: 10.1007/s12094-014-1225-3. Epub 2014 Oct 16.
Abstract | Full text | Related citations


Doctor SM, Tsao CK, Godbold JH, Galsky MD, Oh WK.
Is prostate cancer changing?: evolving patterns of metastatic castration-resistant prostate cancer.
Cancer. 2014 Mar 15;120(6):833-9. doi: 10.1002/cncr.28494. Epub 2013 Dec 30.
Abstract | Related citations


Livi L, Isidori AM, Sherris D, Gravina GL.
Advances in prostate cancer research and treatment.
Biomed Res Int. 2014;2014:708383. doi: 10.1155/2014/708383. Epub 2014 Aug 18. [22 articles, 215 pages]
Abstract | Full text (Complete volume) | Related citations


Nowak JT.
Oligometastatic Prostate Cancer – Still Curable So Be Vigilant.
Malecare Advanced Prostate Cancer Newsletter, 2013 Oct 9.
Abstract | Full text

PROGNOSIS AND OUTCOME



Gandaglia G, Karakiewicz PI, Briganti A, Passoni NM, Schiffmann J, Trudeau V, Graefen M, Montorsi F, Sun M.
Impact of the Site of Metastases on Survival in Patients with Metastatic Prostate Cancer.
Eur Urol. 2014 Aug 6. pii: S0302-2838(14)00672-1. doi: 10.1016/j.eururo.2014.07.020. [Epub ahead of print]
Abstract | Full text | Related citations


Biochemical recurrence

Positive surgical margins

Preston MA, Blute ML.
Positive surgical margins after radical prostatectomy: does it matter?
Eur Urol. 2014 Feb;65(2):314-5. doi: 10.1016/j.eururo.2013.08.037. Epub 2013 Aug 26.
Abstract | Full text | Related citations


Vesely S, Jarolim L, Duskova K, Schmidt M, Dusek P, Babjuk M.
The use of early postoperative prostate-specific antigen to stratify risk in patients with positive surgical margins after radical prostatectomy.
BMC Urol. 2014 Oct 2;14:79. doi: 10.1186/1471-2490-14-79.
Abstract | Full text | Related citations


Cancer-specific mortality

Brockman JA, Alanee S, Vickers AJ, Scardino PT, Wood DP, Kibel AS, Lin DW, Bianco Jr FJ, Rabah DM, Klein EA, Ciezki JP, Gao T, Kattan MW, Stephenson AJ.
Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy.
Eur Urol. 2014 Oct 6. pii: S0302-2838(14)00956-7. doi: 10.1016/j.eururo.2014.09.019. [Epub ahead of print]
Abstract | Related citations


Lee BH, Kibel AS, Ciezki JP, Klein EA, Reddy CA, Yu C, Kattan MW, Stephenson AJ.
Are Biochemical Recurrence Outcomes Similar After Radical Prostatectomy and Radiation Therapy? Analysis of Prostate Cancer-Specific Mortality by Nomogram-predicted Risks of Biochemical Recurrence.
Eur Urol. 2014 Oct 4. pii: S0302-2838(14)00912-9. doi: 10.1016/j.eururo.2014.09.017. [Epub ahead of print]
Abstract | Full text | Related citations


Zumsteg ZS, Zelefsky MJ.
Improved survival with surgery in prostate cancer patients without medical comorbidity: a self-fulfilling prophecy?
Eur Urol. 2013 Sep;64(3):381-3. doi: 10.1016/j.eururo.2013.05.037. Epub 2013 May 28.
Abstract | Full text | Related citations


Clinical recurrence

Clinical progression following biochemical recurrence

Phillips R.
Prostate cancer: Predicting outcomes of recurrence after escalated-dose radiotherapy.
Nat Rev Urol. 2014 Oct 28. doi: 10.1038/nrurol.2014.299. [Epub ahead of print]
Abstract | Related citations


Zumsteg ZS, Spratt DE, Romesser PB, Pei X, Zhang Z, Polkinghorn W, McBride S, Kollmeier M, Yamada Y, Zelefsky MJ.
The Natural History and Predictors of Outcome Following Biochemical Relapse in the Dose Escalation Era for Prostate Cancer Patients Undergoing Definitive External Beam Radiotherapy.
Eur Urol. 2014 Oct 9. pii: S0302-2838(14)00965-8. doi: 10.1016/j.eururo.2014.09.028. [Epub ahead of print]
Abstract | Related citations


Castration-resistant prostate cancer

Spratt DE, Zumsteg ZS, Pei X, Romesser PB, Yamada J, Kollmeier MA, Woo K, Zhang Z, Zelefsky MJ.
Predictors of castration-resistant prostate cancer after dose-escalated external beam radiotherapy.
Prostate. 2014 Oct 18. doi: 10.1002/pros.22902. [Epub ahead of print]
Abstract | Related citations


Intraductal carcinoma of the prostate

Zhao T, Liao B, Yao J, Liu J, Huang R, Shen P, Peng Z, Gui H, Chen X, Zhang P, Zhu Y, Li X, Wei Q, Zhou Q, Zeng H, Chen N.
Is there any prognostic impact of intraductal carcinoma of prostate in initial diagnosed aggressively metastatic prostate cancer?
Prostate. 2014 Oct 13. doi: 10.1002/pros.22906. [Epub ahead of print]
Abstract | Related citations


Noncastrate metastatic prostate cancer

Gravis G, Boher JM, Fizazi K, Joly F, Priou F, Marino P, Latorzeff I, Delva R, Krakowski I, Laguerre B, Walz J, Rolland F, Théodore C, Deplanque G, Ferrero JM, Pouessel D, Mourey L, Beuzeboc P, Zanetta S, Habibian M, Berdah JF, Dauba J, Baciuchka M, Platini C, Linassier C, Labourey JL, Machiels JP, Kouri CE, Ravaud A, Suc E, Eymard JC, Hasbini A, Bousquet G, Soulie M, Oudard S.
Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model.
Eur Urol. 2014 Sep 29. pii: S0302-2838(14)00959-2. doi: 10.1016/j.eururo.2014.09.022. [Epub ahead of print]
Abstract | Related citations

QUALITY OF LIFE



White ID, Wilson J, Aslet P, Baxter AB, Birtle A, Challacombe B, Coe J, Grover L, Payne H, Russell S, Sangar V, Van As N, Kirby M.
Development of UK guidance on the management of erectile dysfunction resulting from radical radiotherapy and androgen deprivation therapy for prostate cancer.
Int J Clin Pract. 2014 Oct 6. doi: 10.1111/ijcp.12512. [Epub ahead of print]
Abstract | Full text | Related citations

STAGING



Castellucci P, Ceci F, Graziani T, Schiavina R, Brunocilla E, Mazzarotto R, Pettinato C, Celli M, Lodi F, Fanti S
Early biochemical relapse after radical prostatectomy: which prostate cancer patients may benefit from a restaging 11C-Choline PET/CT scan before salvage radiation therapy?
J Nucl Med. 2014 Sep;55(9):1424-9. doi: 10.2967/jnumed.114.138313. Epub 2014 Jun 16.
Abstract | Related citations

TREATMENT



Freedland SJ, Rumble RB, Finelli A, Chen RC, Slovin S, Stein MN, Mendelson DS, Wackett C, Sandler HM.
Adjuvant and salvage radiotherapy after prostatectomy: american society of clinical oncology clinical practice guideline endorsement.
J Clin Oncol. 2014 Dec 1;32(34):3892-8. doi: 10.1200/JCO.2014.58.8525. Epub 2014 Nov 3.
Abstract | Full text | Related citations


Miyake M, Tanaka N, Asakawa I, Morizawa Y, Anai S, Torimoto K, Aoki K, Yoneda T, Hasegawa M, Konishi N, Fujimoto K.
Proposed salvage treatment strategy for biochemical failure after radical prostatectomy in patients with prostate cancer: a retrospective study.
Radiat Oncol. 2014 Oct 20;9:208. doi: 10.1186/1748-717X-9-208.
Abstract | Full text | Related citations


Safdieh JJ, Schwartz D, Weiner J, Weiss JP, Rineer J, Madeb I, Rotman M, Schreiber D.
Long-term tolerance and outcomes for dose escalation in early salvage post-prostatectomy radiation therapy.
Radiat Oncol J. 2014 Sep;32(3):179-86. doi: 10.3857/roj.2014.32.3.179. Epub 2014 Sep 30.
Abstract | Full text | Related citations


Taguchi S, Fukuhara H, Azuma T, Suzuki M, Fujimura T, Nakagawa T, Ishikawa A, Kume H, Igawa Y, Homma Y.
Ultra-early versus early salvage androgen deprivation therapy for post-prostatectomy biochemical recurrence in pT2-4N0M0 prostate cancer.
BMC Urol. 2014 Oct 16;14:81. doi: 10.1186/1471-2490-14-81.
Abstract | Full text | Related citations


Taplin ME, Montgomery B, Logothetis CJ, Bubley GJ, Richie JP, Dalkin BL, Sanda MG, Davis JW, Loda M, True LD, Troncoso P, Ye H, Lis RT, Marck BT, Matsumoto AM, Balk SP, Mostaghel EA, Penning TM, Nelson PS, Xie W, Jiang Z, Haqq CM, Tamae D, Tran N, Peng W, Kheoh T, Molina A, Kantoff PW.
Intense Androgen-Deprivation Therapy With Abiraterone Acetate Plus Leuprolide Acetate in Patients With Localized High-Risk Prostate Cancer: Results of a Randomized Phase II Neoadjuvant Study.
J Clin Oncol. 2014 Nov 20;32(33):3705-15. doi: 10.1200/JCO.2013.53.4578. Epub 2014 Oct 13.
Abstract | Related citations


Zhao J, Zhu S, Sun L, Meng F, Zhao L, Zhao Y, Tian H, Li P, Niu Y.
Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies.
PLoS One. 2014 Sep 29;9(9):e107516. doi: 10.1371/journal.pone.0107516. eCollection 2014.
Abstract | Full text | Related citations


Castration-resistant prostate cancer

Houédé N, Pulido M, Mourey L, Joly F, Ferrero JM, Bellera C, Priou F, Lalet C, Laroche-Clary A, Raffin MC, Ichas F, Puech A, Piazza PV.
A Phase II Trial Evaluating the Efficacy and Safety of Efavirenz in Metastatic Castration-Resistant Prostate Cancer.
Oncologist. 2014 Oct 29. pii: theoncologist.2014-0345. [Epub ahead of print]
Abstract | Full text | Related citations


Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT.
Cancer control with radical prostatectomy alone in 1,000 consecutive patients.
J Urol. 2002 Feb;167(2 Pt 1):528-34.
Abstract | Related citations


Isbarn H, Boccon-Gibod L, Carroll PR, Montorsi F, Schulman C, Smith MR, Sternberg CN, Studer UE.
Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks.
Eur Urol. 2009 Jan;55(1):62-75. doi: 10.1016/j.eururo.2008.10.008. Epub 2008 Oct 14.
Abstract | Full text | Related citations


Jang JW, Hwang WT, Guzzo TJ, Wein AJ, Haas NB, Both S, Vapiwala N.
Upfront androgen deprivation therapy with salvage radiation may improve biochemical outcomes in prostate cancer patients with post-prostatectomy rising PSA.
Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):1493-9. doi: 10.1016/j.ijrobp.2011.10.047. Epub 2012 Mar 6.
Abstract | Related citations


Lorente D, Omlin A, Ferraldeschi R, Pezaro C, Perez R, Mateo J, Altavilla A, Zafeirou Z, Tunariu N, Parker C, Dearnaley D, Gillessen S, de Bono J, Attard G.
Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone.
Br J Cancer. 2014 Oct 14. doi: 10.1038/bjc.2014.531. [Epub ahead of print]
Abstract | Related citations


Montorsi F, Berges R, Irani J, Schulman CC.
Hormone Therapy for Prostate Cancer: Exploring Current Controversies.
European Urology Supplements, Volume 8, Issue 9, September 2009, Pages 725–732.
The 2nd World Congress on Controversies in Urology
Abstract | Full text


Thompson TC, Li L.
New targets for resistant prostate cancer.
Oncotarget. 2014 Oct 15;5(19):8816-7.
Abstract | Full text | Related citations